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Abstract
Mucins (MUC) play crucial roles in carcinogenesis and tumor invasion in pancreatic ductal adenocarcinoma (PDAC) and
intraductal papillary mucinous neoplasms (IPMNs). Our immunohistochemistry (IHC) studies have shown a consensus
position on mucin expression profiles in pancreatic neoplasms as follows: MUC1-positive but MUC2-negative expression in
PDACs; MUC1-negative but MUC2-positive expression in intestinal-type IPMNs (dangerous type); MUC1-negative and MUC2-
negative expression in gastric-type IPMNs (safe type); High MUC4 expression in PDAC patients with a poor outcome; and
MUC4-positive expression in intestinal-type IPMNs. We also showed that three mucin genes (MUC1, MUC2 and MUC4)
expression in cancer cell line was regulated by DNA methylation. We have developed a novel ‘methylation-specific
electrophoresis (MSE)’ method to analyze the DNA methylation status of mucin genes by high sensitivity and resolution. By
using the MSE method, we evaluated pancreatic juice samples from 45 patients with various pancreatic lesions. The results
were compared with final diagnosis of the pancreatic lesions including IHC of mucin expression in the paired pancreatic
tissues. The results indicated that the DNA methylation status of MUC1, MUC2 and MUC4 in pancreatic juice matched with
the mucin expression in tissue. Analyses of the DNA methylation status of MUC1, MUC2 and MUC4 were useful for
differential diagnosis of human pancreatic neoplasms, with specificity and sensitivity of 87% and 80% for PDAC; 100% and
88% for intestinal-type IPMN; and 88% and 77% for gastric-type IPMN, respectively. In conclusion, MSE analysis of human
pancreatic juice may provide useful information for selection of treatment for pancreatic neoplasms.
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Introduction
Patients with pancreatic ductal adenocarcinoma (PDAC) have a
poor clinical outcome, despite improvements in diagnosis and
treatment methods. Resection at an early stage gives a relatively
favorable outcome, but PDACs are diagnosed in an advanced
stage in most cases [1]. Indolent neoplasms such as intraductal
papillary mucinous neoplasms (IPMNs) also occur in the pancreas
[2] and sometimes transform into lesions with an invasive
character and a poor outcome [3,4]. An IPMN is a mucin-
producing cystic neoplasm that was first recognized by the World
Health Organization (WHO) in 1996 and renamed by the WHO
as IPMN in 2000 [5]. Currently, IPMNs are the most common
cystic neoplasm of the pancreas, and are classified into gastric,
intestinal, pancreatobiliary, and oncocytic types [2,6]. We have
shown that the outcome of intestinal-type IPMN is poorer than
that of gastric-type IPMN, although the outcomes for both IPMNs
are significantly better than that with PDAC [3,4]. A recent study
also showed that the morphological subtype of IPMN is an
independent prognostic factor: i.e. patients with gastric-type IPMN
have a fair prognosis, those with intestinal-type or oncocytic-type
IPMN have a relatively less favorable prognosis, and those with
pancreatobiliary-type IPMN have the poorest prognosis [6].
Mucins play crucial roles in diagnostic and prognostic
prediction and in carcinogenesis and tumor invasion. MUC1
(pan-epithelial membrane mucin), the first cloned mucin, is an
important human tumor antigen, second only to WT1 in cancer
antigen pilot prioritization using a ranking based on predefined
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and preweighted criteria [7]. Our series of immunohistochemistry
(IHC) studies has shown a consensus position on mucin expression
profiles in pancreatic neoplasms as follows [8,9]: high expression of
MUC1 is observed in PDACs and is related to a poor outcome
[10]; intestinal-type IPMNs are MUC1-negative but MUC2
(intestinal secretory mucin)-positive, and sometimes show invasive
growth with de novo MUC1 expression [3,4,11]; gastric-type
IPMNs that are MUC1-negative and MUC2-negative have a
low potential for malignancy [3,4]; de novo high MUC4 (tracheo-
bronchial mambrane mucin) expression is associated with a poor
outcome in patients with PDAC [12]; and MUC4 expression is
observed mainly in intestinal-type IPMNs [13].
We have also found that the methylation status, mRNA
expression, and mucin core protein expression were well
correlated with each other for MUC1, MUC2, and MUC4 in
cancer cell lines [14,15,16,17]. In addition, we have developed a
novel DNA methylation analysis method ‘methylation specific
electrophoresis (MSE, international patent open: WO 2011/
132798)’. The MSE method greatly decreases the amount of input
DNA and has high sensitivity, although conventional analytical
methods for DNA methylation require a large amount of DNA
and have low sensitivity. The lower detection limit for distinguish-
ing different methylation status is under 0.1% and the detectable
minimum amount of DNA is 20 pg, which can be obtained from
only a few cells, and has high resolution [18]. Application of this
MSE method in analyses of the epigenetic status of MUC1, MUC2
and MUC4 in pancreatic juice may be useful for early detection of
pancreatic lesion, as further investigated in the current study.
Materials and Methods
Cell Lines
Human pancreatic carcinoma cell line HPAF II and Human
colon adenocarcinoma cell lines Caco2 and LS174T were
obtained from the American Type Culture Collection. HPAF II,
Caco2 and LS174T cells were cultured in Eagle’s minimum
essential medium (Sigma, St. Louis, MO, USA). The media was
supplemented with 10% fetal bovine serum (Invitrogen, Minatoku,
Tokyo, Japan) and 100 U/mL of penicillin/100 mg/mL of
streptomycin (Sigma). Cell lines with high and low methylation
of MUC1 (Caco2 and LS174T), MUC2 (HPAF II and LS174T)
and MUC4 (Caco2 and LS174T) were used as control standards in
the MSE analysis.
Clinical Samples
Pancreatic tissues. As a basic experiment for the analysis of
pancreatic juice, we aimed to examine the relationship between
the extent of DNA methylation of mucin genes and the
expression level of mRNA in paired pancreatic tissues. Tissue
blocks (about 26262 mm) were obtained from neoplastic and
non-neoplastic areas of surgically resected fresh specimens of 17
PDACs.
Pancreatic juice. After completion of endoscopic retrograde
pancreatography, pancreatic juice was collected using endoscopic
nasopancreatic drainage, pancreatic stenting, a bottle-shaped
metal tip endoscopic retrograde cholangiopancreatography cath-
eter (5 Fr; MTW Endoskopie Inc., Wesel, Germany) [19,20].
Ethics statement. The study was conducted in accordance
with the guiding principles of the Declaration of Helsinki.
Collection of samples was approved by the ethical committees of
each hospital (Ethical committees of Kagoshima University
Hospital, Chiba Cancer Center Hospital, Osaka Medical College
Hospital, Nanpuh Hospital and Kyoto University Hospital), and
informed written consent was obtained from each patient. All
studies using human materials in this article were approved by the
ethical committee of Kagoshima University Hospital (revised 20–
82 and revised 22–127).
Extraction and Quantification of mRNA
Total RNA was extracted from cell lines, human pancreatic
tissues and pancreatic juices using a RNeasy Mini kit (QIAGEN,
Chuo-ku, Tokyo, Japan). Total RNA (1 mg) was reverse
transcribed with a High Capacity RNA-to-cDNA Kit
Figure 1. Expression level of MUC1 mRNA and methylation status in pancreatic tissue of PDAC specimens. Correlation analysis of
mRNA levels and extent of DNA methylation. The MUC1 U-index showed a strong correlation with the MUC1 mRNA level (R2= 0.406, P,0.001).
Relative mRNA expression was calculated based on the expression level of MUC1 in a human pancreatic cell line (Panc1). The U methylation index (U-
index) was normalized using a cell line (LS-174T) with low methylation.
doi:10.1371/journal.pone.0093760.g001
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(Applied Biosystems, Foster City, CA, USA). Real-time reverse
transcription–PCR was performed on a ABI PRISM 7000
Sequence Detection System using SYBR Green PCR Master
Mix (Applied Biosystems). Gene expression was normalized to the
b-actin mRNA level in each sample. Primer sets are shown in
Table S1.
Figure 2. Correlations between results of pancreatic tissue analysis and fluid analysis. A: Pancreatic juice from patients with PDAC
showed a unmethylated MUC1 (U-index: 65.1 point), methylated MUC2 (U-index: 42.7 point), and unmethylated MUC4 (U-index: 69.4 point) in MSE
analysis, and paired pancreatic tissues were MUC1-positive, MUC2-negative and MUC4-positive in immunohistochemistry (IHC). B: Pancreatic juice
from patients with intestinal-type IPMN showed unmethylated MUC1 (U-index: 76.7 point), unmethylated MUC2 (U-index: 96.0 point) and
unmethylated MUC4 (U-index: 92.2 point)in MSE analysis, and paired pancreatic tissues were MUC1- positive, MUC2- positive and MUC4-positive in
IHC. C: Pancreatic juice from patients with gastric-type IPMN showed unmethylated MUC1(U-index: 22.8 point) and methylated MUC2 (U-index: 4.5
point) and methylated MUC4 (U-index: 46.4 point) in MSE analysis, and paired pancreatic tissues were MUC1-positive and MUC2- negative and MUC4-
negative in IHC. Cell line results of MSE analysis for MUC1, H: highly methylated (Caco2), L: low methylation (LS-174T); for MUC2, H: highly methylated
(HPAF II), L: low methylation (LS-174T); for MUC4, H: highly methylated (Caco2), L: low methylation (LS-174T). Arrows indicate the highest band using
for calculation of U-index.
doi:10.1371/journal.pone.0093760.g002
Table 1. Origin of pancreatic juice samples.
Disease state Number
PDAC 15
Intestinal-type IPMN 8
Other-type IPMN
Pancreatobiliary-type IPMN 4
Intestinal-type IPMN with Colloid Carcinoma 3
Oncocytic-type IPMN 1
Intraductal tubulopapillary neoplasm 1
Gastric-type IPMN 11
Non-neoplastic pancreas 2
Total 45
PDAC: pancreatic ductal adenocarcinoma, IPMN: intraductal papillary mucinous neoplasm.
doi:10.1371/journal.pone.0093760.t001
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Extraction of DNA and Bisulfite Modification
DNA from cell lines, pancreatic tissue, and pancreatic juice was
extracted using a DNeasy Tissue System (QIAGEN). Bisulfite
modification of the genomic DNA was carried out using an Epitect
Bisulfite Kit (QIAGEN). Purification of PCR products was carried
out using a Wizard SV Gel and PCR Clean-Up System (Promega
KK, Chuo-ku, Tokyo, Japan).
MSE Analysis
MSE analysis was performed as follows. In the preparation of
the samples step, the target DNA fragments were amplified by
nested PCR approach using bisulfite treated DNA. The using
primer sets were shown in Table S1. In the electrophoresis step,
the amplicon was applied to the D-Code system (BioRad
Laboratories, Hercules, CA, USA) using polyacrylamide gel with
linear denaturant gradient at 60uC, 70 V for 14 h. The detailed
informations of MSE method were described in our previous study
[18]. The band intensity was measured by Image J software
(National Institutes of Health,http://rsb.info.nih.gov/ij/.). The
unmethylation index (U-index) was calculated as U-index =
(highest band intensity/total band intensity) sample/(highest band
intensity/total band intensity) basal cell line6100. Thus, the U-index
in each sample was normalized using data from a hypomethylated
cell line.
Statistical Analysis
Data were analyzed using the ‘‘R’’ computing environment
[21]. The normality of the data distribution was evaluated by
Kolmogorov-Smirnov test. Differences between groups were
analyzed by Student t-test or Welch t-test. A nonparametric test
of group difference was performed by Mann–Whitney U test.
Correlations were tested using single regression analysis. Qua-
dratic discrimination analysis and canonical discriminant analysis
were performed with the R add-on MASS package [22]. The
threshold value and area under the curve (AUC) were calculated
by receiver operating characteristics (ROC) curve analysis [23]. A
p value,0.05 was considered statistically significant.
Immunohistochemical Staining
IHC was performed in cut sections of pancreatic tumors using
anti-MUC1 monoclonal antibody (MAb) clone 014E (MAb
MUC1/014E, generated by one of us, Suguru Yonezawa) [24];
anti-MUC2 MAb clone Ccp58 (MAb MUC2/Ccp58, Novocastra
Reagents, Leica Biosystems, Newcastle Upon Tyne, UK) and anti-
MUC4 MAb clone 8G7 (MAb MUC4/8G7, generated by one of
us, Surinder K. Batra) [25], using the immunoperoxidase method.
Antigen retrieval was performed using CC1 antigen retrieval
buffer (pH 8.5, EDTA, 37uC, 30 min; Ventana Medical Systems,
Tucson, AZ, USA) for all sections. Following incubation with the
primary antibodies (MAb MUC1/014E diluted 1:5, 37uC,
32 min; MAb MUC2/Ccp58 diluted 1:200, 37uC, 32 min; MAb
MUC4/8G7 diluted 1:3000, 37uC, 32 min) in phosphate buffered
Figure 3. Methylation status of mucin genes obtained from
pancreatic juice in each disease type. For all three mucins, the U-
index was normalized to a cell line with low methylation (LS-174T). A:
For MUC1, gastric-type IPMN had a significantly lower U-index than
PDAC and other IPMN types; that is, the MUC1 promoter was most
methylated (hypermethylated) in gastric-type IPMN. B: For MUC2,
intestinal-type IPMN had a significantly higher U-index than PDAC and
other IPMN types; that is, the MUC2 promoter was most unmethylated
(hypomethylated) in intestinal-type IPMN. C: For MUC4, PDAC and
intestinal-type IPMN had a significantly higher U-index than other-type
IPMN and gastric-type IPMN.
doi:10.1371/journal.pone.0093760.g003
DNA Methylation Analysis for Pancreatic Diagnosis
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saline pH 7.4 (PBS) with 1% bovine serum albumin (BSA), sections
were stained on a Benchmark XT automated slide stainer using a
diaminobenzidine detection kit (UltraView DAB, Ventana Med-
ical Systems). The control staining using normal mouse serum or
PBS-BSA instead of the primary antibodies always showed no
reaction.
Results
DNA Methylation Status and Expression Level of mRNA in
PDAC Tissues
To examine the relationship between the extent of DNA
methylation of mucin genes and the expression level of mRNA in
paired pancreatic tissues, we evaluated 34 tissue samples (17
paired, neoplastic and non-neoplastic areas of PDAC specimens).
A plot of the U-index for MUC1 against the mRNA level for
MUC1 showed a significant correlation (R2=0.406, P,0.001)
(Figure 1). This result indicates that the extent of DNA
methylation status of MUC1 is a trigger for regulation of
expression of MUC1 mRNA in pancreatic tissue.
A plot of the U-index for MUC2 against the mRNA level for
MUC2 showed no significant correlation (data not shown). A plot
of the U-index for MUC4 against the mRNA level for MUC4
showed no significant correlation, either (data not shown).
However, as shown in the following paragraph, the DNA
methylation status of MUC2 and MUC4 could be applied in the
analysis of pancreatic juice.
Correlation between DNA Methylation Status in
Pancreatic Juice and Mucin Expression
Representative cases of comparison of the DNA methylation
status using MSE of pancreatic juice and expression of mucins
examined by IHC in paired pancreatic tissues from PDAC,
intestinal-type IPMN and gastric-type IPMN are shown in
Figure 2. Pancreatic juice from patients with PDAC showed
unmethylated MUC1, methylated MUC2, and unmethylated
MUC4 in MSE analysis, and paired pancreatic tissues were
MUC1-positive, MUC2-negative and MUC4-positive (Figure 2A).
Pancreatic juice from patients with intestinal-type IPMN showed
unmethylated MUC1, unmethylated MUC2 and unmethylated
MUC4, and paired pancreatic tissues were MUC1-positive,
MUC2-positive and MUC4-positive (Figure 2B). Pancreatic juice
from patients with gastric-type IPMN showed unmethylated
MUC1, methylated MUC2 and methylated MUC4, and paired
pancreatic tissues were MUC1-positive and MUC2-negative and
MUC4-negative (Figure 2C). These results indicate that the DNA
methylation status of the three mucin genes (MUC1, MUC2 and
MUC4) in pancreatic juice matches with the expression level of the
three mucins (MUC1, MUC2 and MUC4) in tissue. Thus, MSE
analysis of pancreatic juice may be useful for assessment of mucin
expression levels.
Differences in DNA Methylation among Neoplastic
Lesions in Pancreatic Juice Analysis
To examine differences in DNA methylation of MUC1, MUC2
and MUC4 among pancreatic neoplastic lesions, we evaluated
pancreatic juice samples from 15 patients with PDAC, 11 patients
with gastric-type IPMN, 8 with intestinal-type IPMN, 9 with other
IPMN types, and 2 non-neoplastic pancreases (Table 1). The
promoter methylation status of the three mucins was detected by
MSE and the U-index was calculated using the band intensity.
Interestingly, pancreatic juices obtained from the 2 non-neoplastic
pancreases were similar to those for gastric-type IPMN (data not
T
a
b
le
2
.
C
o
n
t.
1
.
M
U
C
1
P
A
U
C
T
h
.
P
b
A
U
C
T
h
.
0
.9
8
0
0
.5
0
4
4
8
.9
8
0
.1
1
1
0
.6
7
6
6
8
.9
8
IP
M
N
-G
A
vs
O
th
e
r
P
b
A
U
C
T
h
.
0
.1
0
1
0
.6
5
9
4
8
.9
8
a
W
e
lc
h
T
te
st
,
b
M
an
n
-W
h
it
n
e
y
U
te
st
,P
D
A
C
:p
an
cr
e
at
ic
d
u
ct
al
ad
e
n
o
ca
rc
in
o
m
a,
IP
M
N
:i
n
tr
ad
u
ct
al
p
ap
ill
ar
y
m
u
ci
n
o
u
s
n
e
o
p
la
sm
,I
P
M
N
-I
N
:i
n
te
st
in
al
-t
yp
e
IP
M
N
,I
P
M
N
,I
P
M
N
-O
h
:o
th
e
r-
ty
p
e
IP
M
N
,I
P
M
N
-G
A
:g
as
tr
ic
-t
yp
e
IP
M
N
,T
h
.:
T
h
re
sh
o
ld
va
lu
e
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
3
7
6
0
.t
0
0
2
3
.
M
U
C
4
DNA Methylation Analysis for Pancreatic Diagnosis
PLOS ONE | www.plosone.org 6 April 2014 | Volume 9 | Issue 4 | e93760
T
a
b
le
3
.
Su
m
m
ar
y
o
f
p
re
d
ic
ti
ve
m
o
d
e
l
fi
n
d
in
g
s
fo
r
d
is
e
as
e
ty
p
e
in
Q
u
ad
ra
ti
c
d
is
cr
im
in
at
io
n
an
al
ys
is
.
P
ro
b
a
b
il
it
y
o
f
p
re
d
ic
ti
o
n
F
in
a
l
d
ia
g
n
o
si
s
S
e
tt
in
g
o
f
d
is
e
a
se
ty
p
e
P
D
A
C
IP
M
N
-I
N
O
th
e
r
IP
M
N
-G
A
P
re
d
ic
te
d
d
is
e
a
se
ty
p
e
A
c
c
u
ra
c
y
P
D
A
C
P
D
A
C
5
0
.0
%
3
5
.6
%
8
.1
%
6
.3
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
1
.9
%
0
.0
%
2
.7
%
2
5
.4
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
0
.2
%
0
.0
%
5
.4
%
2
4
.5
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
4
8
.3
%
0
.0
%
7
.7
%
4
4
.0
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
5
.4
%
0
.0
%
2
.8
%
2
1
.8
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
7
.2
%
0
.4
%
5
.0
%
1
7
.4
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
7
.2
%
0
.0
%
2
.6
%
2
0
.2
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
7
.2
%
1
.7
%
5
.8
%
1
5
.3
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
4
6
.8
%
9
.0
%
2
1
.8
%
2
2
.3
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
1
.0
%
0
.0
%
2
.8
%
2
6
.2
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
3
.7
%
1
.5
%
7
.2
%
1
7
.7
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
5
7
.2
%
3
.1
%
3
5
.3
%
4
.4
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
3
2
.7
%
7
.2
%
5
6
.7
%
3
.4
%
O
th
e
r
-
P
D
A
C
P
D
A
C
4
5
.2
%
0
.6
%
5
3
.9
%
0
.3
%
O
th
e
r
-
P
D
A
C
P
D
A
C
1
4
.3
%
0
.3
%
2
8
.7
%
5
6
.7
%
IP
M
N
-G
A
-
IP
M
N
-I
N
IP
M
N
-I
N
2
4
.1
%
6
5
.6
%
7
.0
%
3
.3
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
3
4
.5
%
5
2
.5
%
9
.0
%
4
.0
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
2
.1
%
9
1
.1
%
6
.0
%
0
.8
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
6
.5
%
7
5
.4
%
1
7
.8
%
0
.3
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
0
.5
%
9
5
.0
%
4
.3
%
0
.2
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
0
.1
%
8
9
.2
%
1
0
.6
%
0
.0
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
0
.4
%
9
4
.3
%
5
.0
%
0
.2
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
1
.6
%
3
7
.5
%
5
8
.6
%
2
.4
%
O
th
e
r
-
IP
M
N
-P
B
O
th
e
r
3
0
.3
%
0
.9
%
6
8
.5
%
0
.3
%
O
th
e
r
ye
s
IP
M
N
-P
B
O
th
e
r
0
.4
%
6
.7
%
8
6
.2
%
6
.7
%
O
th
e
r
ye
s
IP
M
N
-P
B
O
th
e
r
1
1
.9
%
0
.1
%
8
7
.9
%
0
.1
%
O
th
e
r
ye
s
IP
M
N
-P
B
O
th
e
r
3
8
.8
%
0
.3
%
1
8
.2
%
4
2
.7
%
IP
M
N
-G
A
-
IP
M
N
-I
N
w
it
h
C
C
O
th
e
r
5
.9
%
4
1
.1
%
5
0
.6
%
2
.3
%
O
th
e
r
ye
s
IP
M
N
-I
N
w
it
h
C
C
O
th
e
r
7
2
.5
%
1
.2
%
7
.5
%
1
8
.8
%
P
D
A
C
-
IP
M
N
-I
N
w
it
h
C
C
O
th
e
r
1
2
.9
%
0
.0
%
1
5
.5
%
7
1
.6
%
IP
M
N
-G
A
-
IP
M
N
-O
n
O
th
e
r
1
.2
%
0
.0
%
7
.7
%
9
1
.1
%
IP
M
N
-G
A
-
IT
P
N
O
th
e
r
1
0
.8
%
1
6
.3
%
7
2
.8
%
0
.2
%
O
th
e
r
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
1
.2
%
0
.0
%
8
.0
%
9
0
.8
%
IP
M
N
-G
A
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
2
.2
%
0
.0
%
7
.5
%
9
0
.3
%
IP
M
N
-G
A
ye
s
DNA Methylation Analysis for Pancreatic Diagnosis
PLOS ONE | www.plosone.org 7 April 2014 | Volume 9 | Issue 4 | e93760
shown). The median U-index, 95% confidence interval and p
values in a Kolmogorov-Smirnov test are shown in Table S2. For
MUC1, gastric-type IPMN had a significantly lower U index (P.
0.001) compared to other diseases, including intestinal-type IPMN
and PDAC (Figure 3A). The area under the curve (AUC) for
distinguishing gastric-type IPMN from other neoplasms was 0.803
(ROC curve shown in Figure S1A; U-index threshold of 44.65
points). For MUC2, the intestinal-type IPMN had a significantly
higher U-index (P.0.001) compared to the other neoplasms,
including gastric-type IPMN and PDAC, and the U-index for
gastric-type IPMN was significantly lower (P = 0.002) than that for
PDAC (Figure 3B). The AUC for distinguishing intestinal-type
IPMN from other neoplasms was 0.882 (ROC curve shown in
Figure S1B; U-index threshold of 82.71 points). For MUC4,
gastric-type IPMN had a significantly lower U-index (P= 0.018)
than intestinal-type IPMN (Figure 3C). The AUC for distinguish-
ing gastric-type IPMN from intestinal-type IPMN was 0.740
(ROC curve shown in Figure S1C; U-index threshold of 83.22
points). The threshold values, AUCs, and P values are summarized
in Table 2.
Distinction of Pancreatic Neoplastic Lesions Based on
Aberrant Methylation of Three Mucins
A predictive model for identification of pancreatic disease was
constructed using the U-indexes of MUC1, MUC2 and MUC4
based on quadratic (Table 3) or canonical (Table 4) discriminant
analysis. The model based on quadratic discrimination analysis
had specificity and sensitivity of 87% and 80% for PDAC; 100%
and 88% for intestinal-type IPMN (dangerous type); and 88% and
77% for gastric-type IPMN (safe type) and non-neoplastic case.
With canonical discriminant analysis, the model had a specificity
and sensitivity of 77% and 73% for PDAC; 95% and 88% for
intestinal-type IPMN; and 91% and 69% for gastric-type IPMN.
These data are summarized in Table S3. The accuracies of the
quadratic and canonical discriminant analyses were 76% and
64%, respectively, in examination of 45 pancreatic juice samples.
Thus, quadratic discrimination analysis was more suitable for
construction of the predictive model for pancreatic disease type
using analysis of pancreatic juice.
Discussion
The accumulating evidences suggested that the DNA methyl-
ation in body fluids (e.g., blood, saliva) can be promising
biomarkers for various types of cancer [26,27,28]. Previous studies
also showed that the importance of DNA methylation (such as
cyclin D2, ppENK, NPTX2) in pancreatic juice for the diagnosis
of pancreatic neoplasms [29,30]. In our present study, analyses of
the DNA methylation status of MUC1, MUC2 and MUC4 in
pancreatic juices were useful for differential diagnosis of human
pancreatic neoplasms i.e. PDAC, intestinal-type IPMN and gastric-
type IPMN, with high specificity and sensitivity.
In analyses of pancreatic neoplastic and non-neoplastic tissues of
PDAC samples in this study, we found a strong relationship
between the mRNA expression level and DNA methylation status
for MUC1. This is similar to the results in pancreatic cancer cell
lines in our previous study [14] and suggests that DNA
methylation has a key role in MUC1 regulation in human
pancreatic tissue. Thus, evaluation of the DNA methylation status
of MUC1 can provide important information for diagnosis of
human pancreatic neoplasms. We have reported that MUC2 was
not expressed in PDAC and/or non-neoplastic pancreas
[8,9,10,31]. Similarly, PDAC and non-neoplastic pancreas showed
low expression level of MUC2 mRNA (data not shown). Thus, we
T
a
b
le
3
.
C
o
n
t.
P
ro
b
a
b
il
it
y
o
f
p
re
d
ic
ti
o
n
F
in
a
l
d
ia
g
n
o
si
s
S
e
tt
in
g
o
f
d
is
e
a
se
ty
p
e
P
D
A
C
IP
M
N
-I
N
O
th
e
r
IP
M
N
-G
A
P
re
d
ic
te
d
d
is
e
a
se
ty
p
e
A
c
c
u
ra
c
y
IP
M
N
-G
A
IP
M
N
-G
A
0
.1
%
0
.0
%
6
.1
%
9
3
.8
%
IP
M
N
-G
A
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
7
.2
%
0
.0
%
1
6
.4
%
7
6
.4
%
IP
M
N
-G
A
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
5
.7
%
0
.0
%
1
1
.7
%
8
2
.7
%
IP
M
N
-G
A
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
0
.4
%
0
.0
%
2
1
.7
%
7
7
.9
%
IP
M
N
-G
A
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
7
.5
%
0
.0
%
1
5
.8
%
7
6
.7
%
IP
M
N
-G
A
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
4
4
.1
%
0
.0
%
1
1
.0
%
4
5
.0
%
IP
M
N
-G
A
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
6
1
.3
%
0
.4
%
8
.8
%
2
9
.5
%
P
D
A
C
-
IP
M
N
-G
A
IP
M
N
-G
A
6
6
.7
%
1
1
.7
%
9
.3
%
1
2
.3
%
P
D
A
C
-
IP
M
N
-G
A
IP
M
N
-G
A
6
9
.4
%
2
.3
%
9
.5
%
1
8
.8
%
P
D
A
C
-
P
an
cr
e
at
it
is
IP
M
N
-G
A
1
2
.8
%
0
.3
%
2
6
.1
%
6
0
.8
%
IP
M
N
-G
A
ye
s
N
L
IP
M
N
-G
A
1
.4
%
0
.0
%
8
.0
%
9
0
.6
%
IP
M
N
-G
A
ye
s
P
D
A
C
:p
an
cr
e
at
ic
d
u
ct
al
ad
e
n
o
ca
rc
in
o
m
a,
IP
M
N
:i
n
tr
ad
u
ct
al
p
ap
ill
ar
y
m
u
ci
n
o
u
s
n
e
o
p
la
sm
,I
P
M
N
-I
N
:i
n
te
st
in
al
-t
yp
e
IP
M
N
,I
P
M
N
-P
B
:p
an
cr
e
at
o
b
ili
ar
y-
ty
p
e
IP
M
N
,I
P
M
N
-I
N
w
it
h
C
C
:i
n
te
st
in
al
-t
yp
e
IP
M
N
w
it
h
co
llo
id
ca
rc
in
o
m
a,
IP
M
N
-
O
n
:
o
n
co
cy
ti
c-
ty
p
e
IP
M
N
,
IT
P
N
:
in
tr
ad
u
ct
al
tu
b
u
lo
p
ap
ill
ar
y
n
e
o
p
la
sm
,
IP
M
N
-G
A
:
g
as
tr
ic
-t
yp
e
IP
M
N
,
N
L:
n
o
le
si
o
n
,
O
th
e
r:
O
th
e
r-
ty
p
e
IP
M
N
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
9
3
7
6
0
.t
0
0
3
DNA Methylation Analysis for Pancreatic Diagnosis
PLOS ONE | www.plosone.org 8 April 2014 | Volume 9 | Issue 4 | e93760
T
a
b
le
4
.
Su
m
m
ar
y
o
f
p
re
d
ic
ti
ve
m
o
d
e
l
fi
n
d
in
g
s
fo
r
d
is
e
as
e
ty
p
e
in
C
an
o
n
ic
al
d
is
cr
im
in
an
t
an
al
ys
is
.
P
ro
b
a
b
il
it
y
o
f
p
re
d
ic
ti
o
n
F
in
a
l
d
ia
g
n
o
si
s
S
e
tt
in
g
o
f
d
is
e
a
se
ty
p
e
P
D
A
C
IP
M
N
-I
N
O
th
e
r
IP
M
N
-G
A
P
re
d
ic
te
d
d
is
e
a
se
ty
p
e
A
c
c
u
ra
c
y
P
D
A
C
P
D
A
C
4
8
.6
%
3
3
.8
%
1
5
.3
%
2
.4
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
5
4
.2
%
1
.7
%
4
.2
%
3
9
.9
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
6
1
.0
%
1
1
.1
%
8
.3
%
1
9
.6
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
4
8
.9
%
1
.4
%
1
0
.2
%
3
9
.5
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
6
3
.9
%
5
.0
%
6
.7
%
2
4
.4
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
6
3
.8
%
1
1
.4
%
1
3
.6
%
1
1
.2
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
7
3
.0
%
4
.1
%
8
.1
%
1
4
.7
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
6
3
.4
%
1
3
.8
%
1
5
.1
%
7
.7
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
6
4
.5
%
1
3
.8
%
1
9
.5
%
2
.2
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
5
3
.5
%
1
.5
%
4
.3
%
4
0
.8
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
5
8
.2
%
2
0
.9
%
1
0
.9
%
9
.9
%
P
D
A
C
ye
s
P
D
A
C
P
D
A
C
1
8
.6
%
1
1
.0
%
5
6
.0
%
1
4
.5
%
O
th
e
r
-
P
D
A
C
P
D
A
C
1
8
.4
%
3
0
.1
%
4
1
.2
%
1
0
.3
%
O
th
e
r
-
P
D
A
C
P
D
A
C
1
4
.4
%
1
1
.6
%
7
1
.4
%
2
.6
%
O
th
e
r
-
P
D
A
C
P
D
A
C
2
5
.7
%
0
.7
%
2
2
.4
%
5
1
.2
%
IP
M
N
-G
A
-
IP
M
N
-I
N
IP
M
N
-I
N
3
8
.9
%
4
5
.3
%
1
2
.8
%
2
.9
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
4
1
.4
%
4
2
.8
%
1
4
.5
%
1
.3
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
2
5
.3
%
6
3
.0
%
8
.7
%
2
.9
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
1
3
.0
%
7
7
.8
%
9
.0
%
0
.3
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
1
8
.8
%
7
2
.1
%
7
.0
%
2
.1
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
8
.4
%
8
4
.5
%
6
.3
%
0
.8
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
1
7
.8
%
7
2
.5
%
7
.6
%
2
.2
%
IP
M
N
-I
N
ye
s
IP
M
N
-I
N
IP
M
N
-I
N
2
3
.2
%
1
.0
%
6
1
.9
%
1
3
.8
%
O
th
e
r
-
IP
M
N
-P
B
O
th
e
r
1
4
.5
%
8
.2
%
7
4
.8
%
2
.5
%
O
th
e
r
ye
s
IP
M
N
-P
B
O
th
e
r
6
0
.4
%
2
.2
%
3
3
.8
%
3
.6
%
P
D
A
C
-
IP
M
N
-P
B
O
th
e
r
1
1
.6
%
6
.7
%
8
0
.2
%
1
.4
%
O
th
e
r
ye
s
IP
M
N
-P
B
O
th
e
r
4
5
.1
%
1
.8
%
2
1
.1
%
3
2
.0
%
P
D
A
C
-
IP
M
N
-I
N
w
it
h
C
C
O
th
e
r
1
8
.9
%
5
1
.5
%
2
2
.1
%
7
.6
%
IP
M
N
-I
N
-
IP
M
N
-I
N
w
it
h
C
C
O
th
e
r
5
8
.0
%
2
0
.7
%
1
0
.6
%
1
0
.7
%
P
D
A
C
-
IP
M
N
-I
N
w
it
h
C
C
O
th
e
r
1
9
.9
%
0
.8
%
1
5
.9
%
6
3
.4
%
IP
M
N
-G
A
-
IP
M
N
-O
n
O
th
e
r
8
.2
%
0
.3
%
7
.2
%
8
4
.3
%
IP
M
N
-G
A
-
IT
P
N
O
th
e
r
8
.5
%
7
6
.9
%
1
4
.1
%
0
.5
%
IP
M
N
-I
N
-
IP
M
N
-G
A
IP
M
N
-G
A
6
.9
%
0
.1
%
1
.0
%
9
2
.0
%
IP
M
N
-G
A
ye
s
IP
M
N
-G
A
IP
M
N
-G
A
1
0
.2
%
0
.2
%
4
.5
%
8
5
.0
%
IP
M
N
-G
A
ye
s
DNA Methylation Analysis for Pancreatic Diagnosis
PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e93760
could not examine the correlation between DNA methylation
status (U index) and expression level of mRNA. In MUC4, PDAC
showed higher U index (hypomethylation status of DNA) than
paired non-neoplastic area (data not shown). However, significant
correlation was not found between DNA methylation status (U
index) and expression level of mRNA. This result suggests that
other factors affect MUC4 expression. Although there was no
relationship between the mRNA expression level and DNA
methylation status for MUC2 and MUC4 in the tissue samples,
the DNA methylation status ofMUC2 andMUC4 could be applied
in the analysis of pancreatic juice as follows.
Since MUC1, MUC2 and MUC4 are key mucins in
pathological diagnosis of pancreatic neoplasms [8,9,13,31], our
goal is to apply DNA methylation analysis of the three mucin
genes using pancreatic juice for early diagnosis of these neoplasms.
For this reason, we investigated the DNA methylation status of
MUC1, MUC2 and MUC4 in 45 samples of pancreatic juice
collected from patients with PDAC, intestinal-type IPMN, gastric-
type IPMN, other-type IPMN and non-neoplastic pancreas.
MSE showed that gastric-type IPMNs have a significantly
lower U-index for MUC1 than other pancreatic neoplasms,
indicating that MSE of MUC1 is useful to identify gastric-type
IPMNs. MSE also showed that intestinal type-IPMNs have a
significantly higher U-index for MUC2 compared to other
pancreatic neoplasms and that this can be used to identify
intestinal-type IPMNs. Interestingly, the MUC2 analysis also
showed a significant difference in methylation status between
PDAC and intestinal-type IPMN, and between PDAC and
gastric-type IPMN. Such results may provide a diagnostic clue for
PDAC. In addition, analysis of MUC4 using MSE may allow
intestinal-type IPMN to be distinguished from gastric-type IPMN.
The DNA methylation status of MUC1, MUC2 and MUC4 in the
MSE analysis also matched the expression profiles of the
mucin proteins established in our previous studies
[3,4,8,9,10,12,13,31,32,33,34].
Differentiation of gastric-type IPMN (usually a safe type
with a favorable outcome) from intestinal-type IPMN (a
dangerous type with progression to colloidal carcinoma) by
MSE clearly has a major clinical benefit. MSE also allows
classification of other pancreatic lesions, including pancreat-
obiliary-type IPMN and oncocytic-type IPMN, which some-
times overlap with gastric-type IPMN or intestinal-type IPMN
[35]. Most gastric-type IPMNs do not require surgery, whereas
the other IPMNs usually do need surgical removal [36]. Thus,
there may be a significant clinical benefit of MSE analysis of
mucin genes using pancreatic juice because this analysis can
differentiate IPMNs requiring surgical removal from those that
can be treated conservatively with follow-up. Recently,
development of PDAC derived from gastric-type IPMN was
reported [37]. In the cases of the present study, there is one
case of advanced PDAC derived from gastric-type IPMN. The
result of MSE analysis of that case showed a pattern of PDAC.
Thus, we could differentiate gastric-type IPMN with progres-
sion to PDAC, which needs surgical removal, from pure
gastric-type IPMN, which does not need surgical removal, by
MSE analysis of pancreatic juice.
Pancreatic juice cytology with MUC staining is highly reliable
for identifying the preoperative histological subtype of IPMN [20],
but cannot be applied to pancreatic juice containing no cells. In
contrast, MSE can be used with pancreatic juice containing only
DNA fragments. Cells and proteins are easily degraded in
pancreatic juice due to the presence of strong digestive enzymes,
but DNA fragments may still be present. However, there are many
variables between the DNA methylation status as the starting point
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of mucin synthesis and the final protein product detected by mucin
IHC, including the effects of transcription factors, splicing
variants, post-transcriptional regulation including microRNAs,
and glycosylation. Despite these variables, our MSE analyses of
MUC1, MUC2 and MUC4 in human pancreatic juice showed high
sensitivity and specificity for differentiation among PDAC, gastric-
type IPMN, intestinal-type IPMN and other-type IPMN.
These findings suggest that MSE analysis of human pancreatic
juice can provide useful information for selection of treatment
methods for pancreatic neoplasms. Diagnosis can be made using
this approach alone, but a combination of MSE analysis with
imaging such as ultrasound, computed tomography and magnetic
resonance imaging and also with pancreatic juice cytology with
MUC staining may permit early differential diagnosis and
treatment of pancreatic neoplasms.
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